Therapeutic Action
Antiretroviral, nucleoside reverse transcriptase inhibitor
PDF page 189
Loading InternPractice…
Drug reference
Antiretroviral, nucleoside reverse transcriptase inhibitor
PDF page 189
HIV infection, in combination with other antiretrovirals
PDF page 189
Administer with caution to patients with history of hepatic disorders. May cause: gastrointestinal disturbances (diarrhoea, nausea, vomiting, etc.) and possibly: haematological disorders, especially when combined with zidovudine (neutropenia, anaemia, thrombocytopenia), myopathy, hepatic or pancreatic disorders. Reduce dosage in patients with renal impairment. Pregnancy: no contra-indication
PDF page 190
150 mg tablet 50 mg/5 ml oral solution
PDF page 189
The daily dose is administered once daily or in 2 divided doses. Child 1 month and over and adult: Weight Daily dose 50 mg/5 ml oral sol. 150 mg tablet 3 to < 6 kg 60 mg 3 ml x 2 – 6 to < 10 kg 80 mg 4 ml x 2 – 10 to < 14 kg 120 mg 6 ml x 2 – ½ tab x 2 14 to < 20 kg 150 mg – or 1 tab x 1 ½ tab morning and 1 tab evening 20 to < 25 kg 225 mg – or 1 ½ tab x 1 1 tab x 2 ≥ 25 kg 300 mg – or 2 tab x 1
PDF page 189
Depending on the efficacy and tolerance of lamivudine.
PDF page 190
In neonates, the dosage of lamivudine 50 mg/5 ml (i.e. 10 mg/ml) solution is: 2 to < 3 kg: 0.5 ml 2 times daily (daily dose: 10 mg) 3 to < 4 kg: 0.8 ml 2 times daily (daily dose: 16 mg) 4 to < 5 kg: 1 ml 2 times daily (daily dose: 20 mg) Lamivudine is also used for HIV post-exposure prophylaxis, in combination with other antiretrovirals. Also comes in fixed-dose combinations with other antiretrovirals. Preferably use these formulations when available.
PDF page 190
Below 25 °C Once opened, oral solution keeps for 30 days maximum.
PDF page 190